Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2002

View Archived Issues

FDA requests additional animal study before lifting Vasomax clinical hold

Drug pipeline for bipolar disorder

MLN-2704 enters phase I in androgen-independent prostate cancer

Elan completes sale of Abelcet to Enzon

FDA panel recommends approval of rhBMP for open long bone fractures

Positive opinion for Levitra in E.U.

New inhibitors of GSK-3 and/or ROCK kinase under study at Vertex

AstraZeneca presents novel cannabinoid CB2 agonists as potential analgesic agents

Japan Energy and Sumitomo describe new immunomodulators for cancer and other disorders

Novel Src kinase inhibitors in early development at AstraZeneca

Series of vascular damaging agents and their use in cancer, arthritis, diabetes, etc.

Bayer claims Raf kinase inhibitors with utility in cancer

Inhibitor of novel cancer target is selectively cytotoxic to tumor cells

Positive opinion issued in E.U. for Hepsera

PX-478, the lead in a novel class of HIF-1 inhibitors with excellent antitumor activity

Antiangiogenic/antimetastatic peptide completes preclinical evaluation

Ethypharm and Conba enter into strategic alliance

NeuroSearch and GlaxoSmithKline target depression

Probiodrug and Synt:em to apply Pep:trans technology for the treatment of CNS diseases

Additional primary endpoint data released from phase III Aldurazyme study

New Backgrounder published -- Rhinovirus posted November 20, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...